[go: up one dir, main page]

MA38645B1 - Nouveaux inhibiteurs de cyp17/antiandrogènes - Google Patents

Nouveaux inhibiteurs de cyp17/antiandrogènes

Info

Publication number
MA38645B1
MA38645B1 MA38645A MA38645A MA38645B1 MA 38645 B1 MA38645 B1 MA 38645B1 MA 38645 A MA38645 A MA 38645A MA 38645 A MA38645 A MA 38645A MA 38645 B1 MA38645 B1 MA 38645B1
Authority
MA
Morocco
Prior art keywords
cyp17
antiandrogens
new inhibitors
inhibitors
new
Prior art date
Application number
MA38645A
Other languages
English (en)
Other versions
MA38645A1 (fr
Inventor
Eija Tiainen
Gerd Wohlfahrt
Petteri Rummakko
Arja Karjalainen
Mikko Passiniemi
Pekka Pietikäinen
Anssi Haikarainen
Emilia Väisänen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MA38645A1 publication Critical patent/MA38645A1/fr
Publication of MA38645B1 publication Critical patent/MA38645B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne des composés de formule (i), dans laquelle r
MA38645A 2013-06-11 2014-06-10 Nouveaux inhibiteurs de cyp17/antiandrogènes MA38645B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361833846P 2013-06-11 2013-06-11
PCT/FI2014/000009 WO2014202827A1 (fr) 2013-06-11 2014-06-10 Nouveaux inhibiteurs de cyp17/antiandrogènes

Publications (2)

Publication Number Publication Date
MA38645A1 MA38645A1 (fr) 2018-05-31
MA38645B1 true MA38645B1 (fr) 2018-11-30

Family

ID=51062835

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38645A MA38645B1 (fr) 2013-06-11 2014-06-10 Nouveaux inhibiteurs de cyp17/antiandrogènes

Country Status (21)

Country Link
US (1) US9890139B2 (fr)
EP (1) EP3008042A1 (fr)
JP (1) JP6356790B2 (fr)
KR (1) KR20160019928A (fr)
CN (1) CN105339355B (fr)
AR (1) AR101051A1 (fr)
AU (1) AU2014283150B2 (fr)
CA (1) CA2912166A1 (fr)
CL (1) CL2015003595A1 (fr)
EA (1) EA029280B1 (fr)
HK (1) HK1220690A1 (fr)
MA (1) MA38645B1 (fr)
MX (1) MX2015016943A (fr)
PE (1) PE20160050A1 (fr)
PH (1) PH12015502723A1 (fr)
SA (1) SA515370266B1 (fr)
SG (1) SG11201509449XA (fr)
TW (1) TW201534586A (fr)
UA (1) UA116808C2 (fr)
WO (1) WO2014202827A1 (fr)
ZA (1) ZA201508398B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016118666A1 (fr) 2015-01-20 2016-07-28 Arvinas, Inc. Composés et procédés pour la dégradation ciblée du récepteur des androgènes
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
AR110412A1 (es) * 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
TWI692679B (zh) * 2017-12-22 2020-05-01 美商慧盛材料美國責任有限公司 光阻剝除劑
CN108586443B (zh) * 2018-01-31 2019-11-26 佳木斯大学附属第一医院 一种防治支气管肺癌的药物及其制备方法
CN114235972B (zh) * 2021-10-28 2023-08-22 乳源东阳光药业有限公司 一种测定利格列汀杂质rbp-1含量的方法
WO2023091726A1 (fr) * 2021-11-18 2023-05-25 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase 12 dépendante de la cycline (cdk12)
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN114369030B (zh) * 2022-01-14 2024-10-01 浙江大学衢州研究院 一种2,2,4,4-四甲基-1,3-环丁二胺的制备方法
WO2024230825A1 (fr) * 2023-05-11 2024-11-14 Shenzhen Ionova Life Science Co., Ltd. Nouveaux composés utilisés en tant qu'inhibiteurs de cyp11a1 et leurs procédés d'utilisation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546194A (en) 1984-05-29 1985-10-08 G. D. Searle & Co. Substituted chromanon-2-yl alkanols and derivatives thereof
DE3879024T2 (de) 1987-07-31 1993-10-07 Takeda Chemical Industries Ltd Pyridinium-Derivate, ihre Herstellung und Verwendung.
DE60016039T2 (de) 1999-12-22 2005-08-11 Eli Lilly And Co., Indianapolis Verfahren und verbindungen für die hemmung von mrp1
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
JPWO2003082808A1 (ja) * 2002-04-03 2005-08-04 住友製薬株式会社 ベンズアミド誘導体
WO2005000795A2 (fr) 2003-06-10 2005-01-06 Smithkline Beecham Corporation Composes chimiques
WO2005075426A1 (fr) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procedes de preparation et compositions en comportant
JP2007537236A (ja) 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 筋骨格の脆弱性を治療するためのベンゾニトリル誘導体
WO2006044707A1 (fr) 2004-10-13 2006-04-27 Smithkline Beecham Corporation Composes chimiques
UA85937C2 (uk) 2004-12-21 2009-03-10 Пфайзер Продактс Інк. Макроліди
AP2358A (en) 2005-05-09 2012-01-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use.
EP1888512A2 (fr) 2005-06-06 2008-02-20 Smithkline Beecham Corporation Composes chimiques
US20100216813A1 (en) * 2005-11-30 2010-08-26 Smithkline Beecham Corporation Pyrrolidineanilines
ATE473741T1 (de) * 2006-02-10 2010-07-15 Janssen Pharmaceutica Nv Neue imidazolopyrazolderivate als selektive androgen-rezeptor-modulatoren
WO2007099385A1 (fr) 2006-03-01 2007-09-07 Glenmark Pharmaceuticals S.A. Composés inhibiteurs de dipeptidylpeptidase iv et compositions correspondantes
MX2009001442A (es) 2006-08-09 2009-02-18 Smithkline Beecham Corp Pirrolidinona anilinas como moduladores del receptor de progesterona.
JP2010513568A (ja) 2006-12-19 2010-04-30 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー ピロリジンアニリン類
US8013169B2 (en) 2007-01-12 2011-09-06 Allergan, Inc Naphthylmethylimidizoles as therapeutic agents
WO2009124882A1 (fr) 2008-04-09 2009-10-15 H. Lundbeck A/S Nouvelles pipéridinyl-1,3-dihydrobenzoimidazol-2-ones comme agonistes de m1
WO2009131196A1 (fr) * 2008-04-24 2009-10-29 武田薬品工業株式会社 Dérivé de pyrrolidine substituée et ses utilisations
EP2202232A1 (fr) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. Dérivés du 1,2,4-oxadiazole et leur application thérapeutique
SI2445903T1 (sl) * 2009-06-26 2014-07-31 Novartis Ag 1,3-disubstituirani imidazolidin-2-onski derivati kot inhibitorji CYP 17
SG183192A1 (en) 2010-03-10 2012-09-27 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
US8916553B2 (en) 2010-07-26 2014-12-23 Bristol-Myers Squibb Company Sulfonamide compounds useful as CYP17 inhibitors
CN102372717B (zh) * 2010-08-20 2014-06-18 和记黄埔医药（上海）有限公司 吡咯并嘧啶类化合物及其用途
CN103119045B (zh) * 2010-08-20 2016-02-17 和记黄埔医药（上海）有限公司 吡咯并嘧啶化合物及其用途
US8921368B2 (en) 2011-03-17 2014-12-30 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
EP2520566A1 (fr) 2011-05-06 2012-11-07 Orion Corporation Nouveaux composés pharmaceutiques
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
CA2879606C (fr) * 2012-08-08 2017-01-24 Novartis Ag Azines substituees comme pesticides

Also Published As

Publication number Publication date
AU2014283150B2 (en) 2018-05-10
CN105339355A (zh) 2016-02-17
JP6356790B2 (ja) 2018-07-11
SA515370266B1 (ar) 2018-04-15
CN105339355B (zh) 2018-02-27
AU2014283150A1 (en) 2015-12-03
PE20160050A1 (es) 2016-02-18
CA2912166A1 (fr) 2014-12-24
MX2015016943A (es) 2016-04-25
EA029280B1 (ru) 2018-03-30
JP2016523851A (ja) 2016-08-12
MA38645A1 (fr) 2018-05-31
US9890139B2 (en) 2018-02-13
EP3008042A1 (fr) 2016-04-20
ZA201508398B (en) 2017-06-28
PH12015502723B1 (en) 2016-03-14
CL2015003595A1 (es) 2016-07-08
WO2014202827A1 (fr) 2014-12-24
TW201534586A (zh) 2015-09-16
SG11201509449XA (en) 2015-12-30
AR101051A1 (es) 2016-11-23
KR20160019928A (ko) 2016-02-22
US20160130254A1 (en) 2016-05-12
PH12015502723A1 (en) 2016-03-14
UA116808C2 (uk) 2018-05-10
HK1220690A1 (zh) 2017-05-12
EA201592294A1 (ru) 2016-05-31

Similar Documents

Publication Publication Date Title
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA35926B1 (fr) Pyrrolidine-2-carboxamides substitués
JOP20180103A1 (ar) مركب صيدلاني
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
CO6852084A2 (es) Nuevos compuestos sustituidos con halógeno
CR20130045A (es) Compuestos terapéuticos
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UA110338C2 (xx) Хімічні сполуки
EA201690172A1 (ru) Полиморф ингибиторов syk
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
MA35357B1 (fr) Composes de type anilines
CR20140510A (es) Nucleósidos de espirooxetano de uracilo
CR20130369A (es) Novedosos derivados heterocíclicos
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
GT201500334A (es) Compuestos de 3,4- dihidroisoquinolin-2-(1h)-ilo
TR201900038T4 (tr) GPR6'nın tetrahidropiridopirazin modülatörleri.
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
UA113062C2 (xx) Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону
RS54730B1 (sr) Inhibitori beta sekretaze
EA201691141A1 (ru) Соединения против ccr6
CR20150271A (es) Peptidos como agonistas de oxitocina
MA35086B1 (fr) Compose de triazolopyridine
CR20130539A (es) Triazolopiridinas
CR20120637A (es) Triazolopiridinas sustituidas